Global Hospital-acquired Pneumonia (HAP) Drugs Market is expected to grow at a significant CAGR in the upcoming years as the scope and its applications are increasing across the globe. An acute lower respiratory tract infection that is acquired after at least 48 hours of admission to the hospital is referred to Hospital-acquired Pneumonia (HAP). The most common signs & symptoms include malaise, cough, fever, chills, chest pain, rigor, dyspnea, etc.
The factors that propel the growth of the Hospital-acquired Pneumonia (HAP) Drugs Market include increasing demand, rapid urbanization & industrialization, and product development & technological innovations. In addition, some of the key factors that fuel the market growth include insufficient healthcare infrastructure coupled with lack of proper hygiene in the emerging countries. Also, unmet demand due to lack of available treatment for MDR microorganisms drives the market growth.
On the other hand, rising cases of MDR microorganisms may pose a challenge to the growth of the industry. Hospital-acquired Pneumonia (HAP) Drugs Market is classified on the basis of product type, applications, distribution channel and geography. The market is segmented by product type as Antibacterial, Antifungal and Antiviral. Among product type, Antibacterial segment is expected to account a large share of the Hospital-acquired Pneumonia (HAP) Drugs Industry. Hospital-acquired Pneumonia (HAP) Drugs Market is classified on applications as Hospitals, Clinics and others. HAP Drugs Market is segmented by distribution channel as online stores, specialty stores and others.
Hospital-acquired Pneumonia (HAP) Drugs Market is classified on the basis of geography as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific, Japan and Middle East and Africa. The North American region consists of the U.S., and Canada. Latin America region consists of Mexico and Brazil. The Western European region consists of Germany, Italy, France, England and Spain. The Eastern European region consists of Poland and Russia. Asia Pacific region consists of China, India, ASEAN, Australia & New Zealand. The Middle East and African region consists of GCC, South Africa and North Africa.
In case of geographical region, North America is projected to hold a major share in the HAP Drugs industry. The key factors that attribute to the growth of this region include high incidence of pneumonia and hospital acquired infection, presence of key market players, and enhanced quality of treatment. Some of the key players that fuel the growth of the Hospital-acquired Pneumonia (HAP) Drugs Market include GlaxoSmithKline, Merck, Pfizer, and Novartis.
The other prominent players operating in the Hospital-acquired Pneumonia (HAP) Drugs Industry include Arsanis, AstraZeneca, Combioxin, Mylan, Sun Pharmaceutical Industries, Shinogi, Theravance Biopharma, Teva Pharmaceutical, The Medicines Company, and others. The key players are focusing on inorganic growth to sustain themselves amidst fierce competition. As such, mergers, acquisitions, and joint ventures are the need of the hour.
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Hospital-acquired Pneumonia (HAP) Drugs in these regions, from 2013 to 2025 (forecast), covering
• North America
• Southeast Asia
Global Hospital-acquired Pneumonia (HAP) Drugs market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
• Teva Pharmaceutical Industries
• Sun Pharmaceutical Industries
• The Medicines Company
• Theravance Biopharma
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
Research Support Specialist, USA